Compare Stocks

→ [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.57	$0.70	$0.50 ▼ $1.95	$6.15M	1.62	21,351 shs	2,462 shs
DMAC DiaMedica Therapeutics	$2.51 +5.0%	$2.82	$1.50 ▼ $4.75	$95.28M	1.69	42,248 shs	21,158 shs
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs
TORC resTORbio	$2.00 +2.6%	$12.16	$0.86 ▼ $10.50	$72.91M	2.43	1.15 million shs	303,289 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	-14.37%	-4.67%	-3.03%	-55.83%
DMAC DiaMedica Therapeutics	+5.02%	+5.02%	-8.73%	-2.71%	+45.93%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-98.71%
TORC resTORbio	+2.56%	-9.09%	-8.68%	-19.35%	-67.64%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	1.1762 of 5 stars	3.5	3.0	0.0	0.0	1.9	0.0	0.0
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	2.00	Hold	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	178.88% Upside
PLXP PLx Pharma	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest PLXP, DMAC, ADXS, and TORC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$10K	614.90	N/A	N/A	($2.27) per share	-0.25
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00
TORC resTORbio	N/A	N/A	N/A	N/A	$2.24 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$7.98	N/A	∞	N/A	N/A	-3,967.23%	-339.10%	5/21/2024 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A
TORC resTORbio	-$82.74M	-$2.41	N/A	N/A	N/A	N/A	-78.12%	-71.63%	N/A

Latest PLXP, DMAC, ADXS, and TORC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	0.30	0.30
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
PLXP PLx Pharma	N/A	4.79	4.28
TORC resTORbio	N/A	20.69	20.69

Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
DMAC DiaMedica Therapeutics	10.12%
PLXP PLx Pharma	21.19%
TORC resTORbio	46.19%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
DMAC DiaMedica Therapeutics	7.20%
PLXP PLx Pharma	8.95%
TORC resTORbio	11.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	N/A	10.75 million	10.68 million	Not Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable
TORC resTORbio	N/A	36.45 million	N/A	Not Optionable

PLXP, DMAC, ADXS, and TORC Headlines

Source	Headline
	Adicet Bio Inc (ACET) investing.com - January 30 at 1:54 PM
	Targeting the biology of aging with mTOR inhibitors - Nature.com news.google.com - May 4 at 10:20 PM
	PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLive news.google.com - March 17 at 7:14 PM
	Michelle Chaka Joins Torc as Senior Vice President, Safety and Regulatory finance.yahoo.com - February 24 at 7:08 PM
	Torc names regulatory, safety SVP virginiabusiness.com - February 24 at 7:08 PM
	Global AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPR news.google.com - February 8 at 10:13 AM
	Phenotypic Presentations and the Management of Moderate to ... - Healio news.google.com - January 31 at 2:37 PM
	Aerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.com news.google.com - January 23 at 3:41 PM
	Aerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswire news.google.com - January 23 at 8:44 AM
	TinOne Resources Inc. (TORC.V) finance.yahoo.com - January 10 at 8:39 AM
	resTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities News news.google.com - December 16 at 11:48 PM
	resTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities News news.google.com - December 12 at 10:01 PM
	Brian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technology news.google.com - November 3 at 9:25 PM
	TORC Investments, LLC gwinnettdailypost.com - October 6 at 9:57 AM
	Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes forbes.com - September 19 at 2:52 PM
	Fast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journals bizjournals.com - September 12 at 7:31 PM
	Cellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPR openpr.com - September 6 at 7:33 AM
	For preventing aging, some decades old drugs? - BioWorld Online bioworld.com - July 18 at 10:42 PM
	Form DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.com streetinsider.com - July 8 at 2:10 AM
	Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.com gurufocus.com - June 21 at 9:11 PM
	The Best Hand Creams - Don't Waste Your Money dontwasteyourmoney.com - June 18 at 1:34 PM
	Time Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino's CEO gig - Endpoints News endpts.com - June 3 at 11:42 PM
	Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TV kulr8.com - June 3 at 11:42 PM
	Terns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.com streetinsider.com - June 1 at 9:12 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals

NASDAQ:ADXS

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

resTORbio

NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial